Investment Analysts’ Weekly Ratings Updates for Solventum (SOLV)

A number of research firms have changed their ratings and price targets for Solventum (NYSE: SOLV):

• 12/2/2025 – Solventum was upgraded by analysts at BTIG Research from a “neutral” rating to a “buy” rating. They now have a $100.00 price target on the stock.
• 12/2/2025 – Solventum was upgraded by analysts at BTIG Research from a “neutral” rating to a “buy” rating. They now have a $100.00 price target on the stock.
• 12/1/2025 – Solventum was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 11/23/2025 – Solventum was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 11/21/2025 – Solventum had its “neutral” rating reaffirmed by analysts at UBS Group AG.
• 11/15/2025 – Solventum was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 11/10/2025 – Solventum had its price target raised by analysts at UBS Group AG from $77.00 to $79.00. They now have a “neutral” rating on the stock.
• 11/7/2025 – Solventum had its price target raised by analysts at Piper Sandler from $94.00 to $98.00. They now have an “overweight” rating on the stock.
• 10/30/2025 – Solventum had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 10/8/2025 – Solventum had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.